Recent Updates
Recently added Catalysts
ONCY

VOTING RESULTS ex99.htm ONCOLYTICS BIOTECH INC. Annual General Meeting Held on

Key Takeaway: ONCOLYTICS BIOTECH INC. Annual General Meeting Held on May 11, 2011 REPORT OF VOTING RESULTS Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations Matter Voted Upon Outcome of Vote 1. Fixing the number of directors of the issuer for the

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
REOLYSIN
Phase 3 · Carcinoma, Squamous Cell of the Head and Neck

Full Press Release Details

ONCOLYTICS BIOTECH INC.
Annual General Meeting
Held on May 11, 2011
REPORT OF VOTING RESULTS
Pursuant to Section 11.3 of
National Instrument 51-102 - Continuous Disclosure Obligations
Matter Voted Upon Outcome of Vote
1. Fixing the number of directors of the issuer for the ensuing year at nine (9). Approved
2. Appointing the following individuals as directors of the issuer to hold office until the next annual meeting of the issuer or until their successors are appointed or elected: (a) Bradley G. Thompson; (b) Matthew C. Coffey; (c) Ger van Amersfoort; (d) William A. Cochrane; (e) Jim Dinning; (f) Ed Levy; (g) J. Mark Lievonen; (h) Robert B. Schultz; and (i) Fred A. Stewart; Approved
3. Appointing Ernst & Young, LLP, Chartered Accountants, as auditors of the issuer to hold office until the next annual meeting or until their successors are appointed and authorizing the directors of the issuer to fix the remuneration to be paid to the auditors. Approved
Last updated: Jun 3, 2011